Literature DB >> 22012607

[Role of FDG-PET in Staging and Therapy of Children with Hodgkin Lymphoma].

R Kluge1, D Körholz.   

Abstract

The paediatric Hodgkin lymphoma treatment optimisation concepts aim at reduction of treatment intensity with preservation of the high cure rates. A negative interim FDG-PET result after 2 cycles of chemotherapy is associated with a good prognosis. In the current EuroNet-PHL-C1 study radiotherapy is being omitted, if interim PET becomes negative. In addition to the early interim PET after 2 cycles of chemotherapy, all patients undergo an initial PET investigation which is part of the staging processs and plays an essential role for the interpretation of the interim PET. Skeletal involvement can be detected by a typical FDG-PET uptake pattern with high sensitivity and specifity. Therefore, in the forthcoming EuroNet-PHL-C2 study bone marrow biopsy and bone scintigraphy will no longer be part of the staging algorithm. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22012607     DOI: 10.1055/s-0031-1287834

Source DB:  PubMed          Journal:  Klin Padiatr        ISSN: 0300-8630            Impact factor:   1.349


  11 in total

1.  Bone marrow necrosis in a girl with Hodgkin's disease.

Authors:  Herwig Lackner; Volker Strenger; Petra Sovinz; Christine Beham-Schmid; Alexander Pilhatsch; Martin Benesch; Wolfgang Schwinger; Raphael Ulreich; Sandrin Schmidt; Christian Urban
Journal:  Support Care Cancer       Date:  2012-07-08       Impact factor: 3.603

2.  Can treatment of pediatric Hodgkin's lymphoma be improved by PET imaging and proton therapy?

Authors:  B Knäusl; C Lütgendorf-Caucig; J Hopfgartner; K Dieckmann; L Kurch; T Pelz; R Pötter; D Georg
Journal:  Strahlenther Onkol       Date:  2012-11-18       Impact factor: 3.621

Review 3.  FDG PET/CT in children and adolescents with lymphoma.

Authors:  Regine Kluge; Lars Kurch; Françoise Montravers; Christine Mauz-Körholz
Journal:  Pediatr Radiol       Date:  2013-03-24

4.  Impact of rs12917 MGMT Polymorphism on [18F]FDG-PET Response in Pediatric Hodgkin Lymphoma (PHL).

Authors:  Stefanie Kewitz-Hempel; Lars Kurch; Michaela Cepelova; Ines Volkmer; Axel Sauerbrey; Elke Conrad; Stephanie Knirsch; Gabriele Pöpperl; Daniel Steinbach; Ambros J Beer; Christof M Kramm; Carsten-Oliver Sahlmann; Bernhard Erdlenbruch; Wolf-Dieter Reinbold; Andreas Odparlik; Osama Sabri; Regine Kluge; Martin S Staege
Journal:  Mol Imaging Biol       Date:  2019-12       Impact factor: 3.488

5.  qPET - a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma.

Authors:  Dirk Hasenclever; Lars Kurch; Christine Mauz-Körholz; Andreas Elsner; Thomas Georgi; Hamish Wallace; Judith Landman-Parker; Angelina Moryl-Bujakowska; Michaela Cepelová; Jonas Karlén; Ana Álvarez Fernández-Teijeiro; Andishe Attarbaschi; Alexander Fosså; Jane Pears; Andrea Hraskova; Eva Bergsträsser; Auke Beishuizen; Anne Uyttebroeck; Eckhard Schomerus; Osama Sabri; Dieter Körholz; Regine Kluge
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-03-07       Impact factor: 9.236

6.  PET/MRI in cancer patients: first experiences and vision from Copenhagen.

Authors:  Andreas Kjær; Annika Loft; Ian Law; Anne Kiil Berthelsen; Lise Borgwardt; Johan Löfgren; Camilla Bardram Johnbeck; Adam Espe Hansen; Sune Keller; Søren Holm; Liselotte Højgaard
Journal:  MAGMA       Date:  2012-12-25       Impact factor: 2.310

7.  FDG-PET Response Prediction in Pediatric Hodgkin's Lymphoma: Impact of Metabolically Defined Tumor Volumes and Individualized SUV Measurements on the Positive Predictive Value.

Authors:  Amr Elsayed M Hussien; Christian Furth; Stefan Schönberger; Patrick Hundsdoerfer; Ingo G Steffen; Holger Amthauer; Hans-Wilhelm Müller; Hubertus Hautzel
Journal:  Cancers (Basel)       Date:  2015-01-28       Impact factor: 6.639

8.  Inter-Reader Reliability of Early FDG-PET/CT Response Assessment Using the Deauville Scale after 2 Cycles of Intensive Chemotherapy (OEPA) in Hodgkin's Lymphoma.

Authors:  Regine Kluge; Lidia Chavdarova; Martha Hoffmann; Carsten Kobe; Bogdan Malkowski; Françoise Montravers; Lars Kurch; Thomas Georgi; Markus Dietlein; W Hamish Wallace; Jonas Karlen; Ana Fernández-Teijeiro; Michaela Cepelova; Lorrain Wilson; Eva Bergstraesser; Osama Sabri; Christine Mauz-Körholz; Dieter Körholz; Dirk Hasenclever
Journal:  PLoS One       Date:  2016-03-10       Impact factor: 3.240

9.  Abdomen/pelvis computed tomography in staging of pediatric Hodgkin Lymphoma: is it always necessary?

Authors:  Piero Farruggia; Giuseppe Puccio; Alessandra Sala; Alessandra Todesco; Monica Terenziani; Rosamaria Mura; Salvatore D'Amico; Tommaso Casini; Clara Mosa; Marta Pillon; Maria Paola Boaro; Gaetano Bottigliero; Roberta Burnelli; Caterina Consarino; Fausto Fedeli; Maurizio Mascarin; Katia Perruccio; Elisabetta Schiavello; Angela Trizzino; Umberto Ficola; Alberto Garaventa; Mario Rossello
Journal:  Cancer Med       Date:  2016-08-03       Impact factor: 4.452

10.  PET/MR in children. Initial clinical experience in paediatric oncology using an integrated PET/MR scanner.

Authors:  Franz Wolfgang Hirsch; Bernhard Sattler; Ina Sorge; Lars Kurch; Adrian Viehweger; Lutz Ritter; Peter Werner; Thies Jochimsen; Henryk Barthel; Uta Bierbach; Holger Till; Osama Sabri; Regine Kluge
Journal:  Pediatr Radiol       Date:  2013-01-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.